A year after British pharmaceutical giant, GlaxoSmithKline exited Nigeria and asthmatic patients who depended on its inhalers faced significant distress due to the medication’s scarcity ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

or GSK, after promising to cap the out-of-pocket cost of inhalers at $35. Instead, GSK shifted production to another company through a licensing agreement, avoiding required payments to Medicaid ...

GlaxoSmithKline is recalling more than 593,000 asthma inhalers in the US due to a defect that may cause them to deliver fewer doses of the medicine than indicated. The company said it would be ...

Both inhalers provide the advantage of once-daily ... paid by CMS for comparator drugs remain undisclosed. Price Action: GSK stock is up 2.55% at $38.92 at the last check Tuesday.

GSK plans U.S. launch in second half of the year GSK expects Blujepa and other drugs to contribute to over £2 billion in peak sales Blujepa's unique action reduces bacterial resistance risk, GSK ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa, also ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

Gov. Josh Shapiro announced in October GSK’s $800 million project that is expected to create at least 200 new jobs and retain ...